Once-weekly epoetin beta therapy in patients with solid tumours and chemotherapy-induced anaemia: A randomized, double-blind, dose-finding study

European Journal of Cancer Care

Volumn 17, Issue 6, 2008, Pages 619-623

  Heras, P ^a,b   Kritikos, K ^a,b   Hatzopoulos, A ^b   Mitsibounas, D ^b  

^a General Hospital of Kos   (Greece)

^b Hellenic Medical Society for the Study of Psychosomatic Problems   (Greece)

Author keywords

Anaemia; Cancer; Epoetin beta; Haemoglobin; Quality of life

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; NEOPLASM; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANEMIA; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 54349097825     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2007.00892.x     Document Type: Article

References (25)

1. Allain J.-P. (2003) Transfusion risks of yesterday and today. Transfusion Clinique Et Biologique 10, 1 5.
2. Barret-Lee P.J., Bailey N.P., O'Brien M.E. Wager E. (2000) Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. British Journal of Cancer 82, 93 97.
3. Bogdanos J., Karamanolakis D., Milathianakis K., Repousis P., Chloraki-Bobota A., Majed H., Pagalou-Thoua E., Tsintavis A. Koutsilieris M. (2004) Epoetin beta (NeoRecormon) corrects anaemia in patients with hormone-refractory prostate cancer and bone metastases. Anticancer Research 24, 1957 1961.
4. Bokemeyer C., Aapro M.S., Coirdi A., Foubert J., Link H., Osterborg A., Repetto L. Soubeyren P. (2004) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. European Journal of Cancer 40, 2201 2216.
5. Boogaerts M., Coiffier B. Kainz C. (2003) Epoetin beta QOL Working Group. Impact of epoetin beta on quality of life in patients with malignant disease. British Journal of Cancer 88, 988 995.
6. ®) therapy in patients with solid tumours receiving platinum and non-platinum chemotherapy: a meta-analysis. Anticancer Research 25, 479 484.
7. Bosanquet N. Tolley K. (2003) Treatment of anaemia in cancer patients: implications for supportive care in the National Health Service Cancer Plan. Current Medical Research and Opinion 19, 643 650.
8. Cazzola M., Beguin Y., Kloczko J., Spicka I. Coiffier B. (2003) Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. British Journal of Haematology 122, 386 393.
9. Cella D. (1998) Factors influencing quality of life in cancer patients: anaemia and fatigue. Seminars in Oncology 25 (3 Suppl. 7 43 46.
10. Crawford J., Cella D., Cleeland C.S., Cremieux P.Y., Demetri G.D., Sarokhan B.J., Slavin M.B. Glaspy J.A. (2002) Relationship between changes in haemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95, 888 895.
11. Ludlam C.A. Turner M.L. (2006) Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products. British Journal of Haematology 132, 13 24.
12. Ludwig H. Fritz E. (1998) Anaemia in cancer patients. Seminars in Oncology 25 (3 Suppl. 7 2 6.
13. McCormack H.M., Horne D.J. Sheather S. (1988) Clinical applications of visual analogue scales: a critical review. Psychological Medicine 18, 1007 1019.
14. Mercadante S., Gebbia V., Marazzo A. Filosto S. (2000) Anaemia in cancer: pathophysiology and treatment. Cancer Treatment Reviews 26, 303 311.
15. Miller C.B., Jones R.J., Piantadosi S., Abeloff M.D. Spivak J.L. (1990) Decreased erythropoietin response in patients with the anemia of cancer. The New England Journal of Medicine 322, 1689 1692.
16. Mortimer P.P. (2002) Making blood safer. British Medical Journal 325, 400 401.
17. Oberhoff C., Neri B., Amadori D., Petry K.U., Gamucci T., Rebmann U., Nowrousina M.R., Voigtmann R., Monfardini S., Armand J.P., Hermann R., Netter-Pinon J., Tubiana-Mathieu N. Zwierzina H. (1998) Recombinant human erythropoietin in the treatment of chemotherapy-induced anaemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Annals of Oncology 9, 255 260.
18. Osterborg A. (1998) Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: what have we learned? Medical Oncology 15 (Suppl. 1 S47 S49.
19. Osterborg A., Brandberg Y., Molostova V., Losava G., Abdulkadyrov K., Hedenus M. Messinger D. (2002) Epoetin Beta Hematology Study Group. Randomized, double-blind, placebo-controlled trial of recombinant human ertythropoietin, epoetin beta, in hematologic malignancies. Journal of Clinical Oncology 20, 2486 2494.
20. Priestman T.J. Baum M. (1976) Evaluation of quality of life in patients receiving treatment for advanced breast cancer. Lancet 1, 899 900.
21. Provan D. (1999) Better blood transfusion. British Medical Journal 318, 1435 1436.
22. Pujade-Lauraine E. Topham C. (2005) Once-weekly treatment of anemia in patients with cancer: a comparative review of epoetins. Oncology 68, 122 129.
23. Sandler S.G., Yu, H. Rassai N. (2003) Risks of blood transfusion and their prevention. Clinical Advances in Hematology and Oncology 1, 307 313.
24. Ten Bokkel Huinink W.W., de Swart C.A., van Toorn D.W., Morack G., Breed W.P., Hillen H.F., van der Hoeven J.J., Reed N.S., Fairlamb D.J., Chan S.Y., Godfrey K.A., Kristensen G.B., van Tinteren H. Ehmer B. (1998) Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Medical Oncology 15, 174 182.
25. Yellen S.B., Cella D.F., Webster K., Blendowski C. Kaplan E. (1997) Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measuring system. Journal of Pain and Symptom Management 13, 63 74.